OX40:OX40L axis: Emerging targets for improving poxvirus-based CD8 + T-cell vaccines against respiratory viruses

Immunological Reviews

Volumn 244, Issue 1, 2011, Pages 149-168

  Goulding, John ^a   Tahiliani, Vikas ^a   Salek Ardakani, Shahram ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

CD8 + T cells; Influenza; Lung; OX40 OX40L; Poxviruses; Vaccines

Indexed keywords

CD134 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CD30 LIGAND; CD70 ANTIGEN; DEATH RECEPTOR 4; FAS ANTIBODY; GAG PROTEIN; GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 15; INTERLEUKIN 7; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OX40 LIGAND; POXVIRUS VACCINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

CACHEXIA; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); COPENHAGEN RAT; CORONAVIRUS; CORYNEBACTERIUM DIPHTHERIAE; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINE ENCEPHALOMYELITIS VIRUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OTITIS MEDIA; PARAINFLUENZA VIRUS; PERTUSSIS; PLASMODIUM; POXVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; VIRUS VIRULENCE; WEIGHT REDUCTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; GENE EXPRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOLOGIC MEMORY; MICE; MICE, KNOCKOUT; OX40 LIGAND; POXVIRIDAE; POXVIRIDAE INFECTIONS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY SYSTEM; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 80054850036     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2011.01062.x     Document Type: Review

References (189)

1. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008;8:142-152.
2. Snelgrove RJ, Godlee A, Hussell T. Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol 2011;32:328-334.
3. Wissinger E, Goulding J, Hussell T. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin Immunol 2009;21:147-155.
4. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-220.
5. Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11:S5-S11.
6. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007;25:1361-1366.
7. Mizgerd JP. Lung infection - a public health priority. PLoS Med 2006;3:e76.
8. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA 2001;285:535-539.
9. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
10. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 2005;3:591-600.
11. Beigel JH, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385.
12. Lipscomb MF, Hutt J, Lovchik J, Wu T, Lyons CR. The pathogenesis of acute pulmonary viral and bacterial infections: investigations in animal models. Annu Rev Pathol 2010;5:223-252.
13. Wroblewska M. New developments in vaccines against respiratory viruses. Curr Opin Investig Drugs 2008;9:846-855.
14. Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. Annu Rev Immunol 2009;27:61-82.
15. Hanage WP, Fraser C, Tang J, Connor TR, Corander J. Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. Science 2009;324:1454-1457.
16. Brown KF, et al. Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine 2010;28:4235-4248.
17. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010;28:4895-4902.
18. Donnelly CA, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 2004;4:672-683.
19. Reed KD, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004;350:342-350.
20. Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007;2:17-34.
21. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-S53.
22. Yu X, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008;455:532-536.
23. Dormitzer PR, et al. Influenza vaccine immunology. Immunol Rev 2011;239:167-177.
24. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010;115:1678-1689.
25. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med 2005;11:S25-S32.
26. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010;33:451-463.
27. Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 2008;10:1024-1029.
28. Ehrhardt C, Seyer R, Hrincius ER, Eierhoff T, Wolff T, Ludwig S. Interplay between influenza A virus and the innate immune signaling. Microbes Infect 2010;12:81-87.
29. Sanders CJ, Doherty PC, Thomas PG. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res 2011;343:13-21.
30. McGill J, Heusel JW, Legge KL. Innate immune control and regulation of influenza virus infections. J Leukoc Biol 2009;86:803-812.
31. Woodland DL, Scott I. T cell memory in the lung airways. Proc Am Thorac Soc 2005;2:126-131.
32. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009;9:153-161.
33. Legge KL, Braciale TJ. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 2003;18:265-277.
34. Bajenoff M, Granjeaud S, Guerder S. The strategy of T cell antigen-presenting cell encounter in antigen-draining lymph nodes revealed by imaging of initial T cell activation. J Exp Med 2003;198:715-724.
35. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-159.
36. Mempel TR, Scimone ML, Mora JR, von Andrian UH. In vivo imaging of leukocyte trafficking in blood vessels and tissues. Curr Opin Immunol 2004;16:406-417.
37. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004;5:1235-1242.
38. + T cells during an acute virus infection. Immunity 1998;8:167-175.
39. Crowe SR, Miller SC, Woodland DL. Identification of protective and non-protective T cell epitopes in influenza. Vaccine 2006;24:452-456.
40. Topham DJ, Castrucci MR, Wingo FS, Belz GT, Doherty PC. The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia. J Immunol 2001;167:6983-6990.
41. + T cell response in the lungs following murine influenza virus infection. J Immunol 2009;183:4177-4181.
42. + T cell survival during influenza virus infection. J Exp Med 2010;207:521-534.
43. + T cell responses require interactions with dendritic cells in the lungs. J Exp Med 2008;205:1635-1646.
44. + T cells to the lung airways following influenza infection. J Immunol 2011;186:174-182.
45. Woodland DL, Dutton RW. Heterogeneity of CD4(+) and CD8(+) T cells. Curr Opin Immunol 2003;15:336-342.
46. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
47. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge. Immunity 2010;33:96-105.
48. Hikono H, et al. T-cell memory and recall responses to respiratory virus infections. Immunol Rev 2006;211:119-132.
49. + T cells. J Exp Med 2007;204:1625-1636.
50. Roberts AD, Ely KH, Woodland DL. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 2005;202:123-133.
51. + T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol 2004;172:6533-6537.
52. + T cells and antiviral protection. J Immunol 2005;175:4677-4685.
53. Esser MT, et al. Memory T cells and vaccines. Vaccine 2003;21:419-430.
54. + T-cell memory. Nat Rev Immunol 2008;8:107-119.
55. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258.
56. + T cell efficacy in vaccination and disease. Nat Med 2008;14:623-628.
57. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis 1985;151:81-88.
58. Frank AL, Taber LH, Wells JM. Individuals infected with two subtypes of influenza A virus in the same season. J Infect Dis 1983;147:120-124.
59. Woodland DL, et al. Antiviral memory T-cell responses in the lung. Microbes Infect 2002;4:1091-1098.
60. Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994;152:1653-1661.
61. + T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683-691.
62. + cells persist in the lungs following recovery from respiratory virus infections. J Immunol 2001;166:1813-1822.
63. + T-cell memory determined by clonal burst size. Nature 1994;369:652-654.
64. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med 1991;174:969-974.
65. Tanchot C, Lemonnier FA, Perarnau B, Freitas AA, Rocha B. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 1997;276:2057-2062.
66. + T cells in MHC class I-deficient mice. Science 1999;286:1377-1381.
67. Gray D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002;2:60-65.
68. Surh CD, Boyman O, Purton JF, Sprent J. Homeostasis of memory T cells. Immunol Rev 2006;211:154-163.
69. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-862.
70. + T cells to the lung airways during respiratory virus infections. J Immunol 2003;170:1423-1429.
71. + T cell memory generation. J Exp Med 2005;202:697-706.
72. + T cell activation and migration. Immunity 2006;24:439-449.
73. + T cells in the lung airways. J Immunol 2007;178:4721-4725.
74. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009;183:6883-6892.
75. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010;16:224-227.
76. Salek-Ardakani S, et al. The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest 2011;121:296-307.
77. + T cells. J Immunol 2011;186:6667-6671.
78. + T cells to be activated by residual antigen. J Exp Med 2010;207:1153-1160.
79. Liu MA. Immunologic basis of vaccine vectors. Immunity 2010;33:504-515.
80. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011;23:377-382.
81. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 1995;58:1-13.
82. Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011;239:8-26.
83. Jacobs BL, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res 2009;84:1-13.
84. Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol 2008;18:217-231.
85. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006;211:320-337.
86. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982;79:4927-4931.
87. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982;79:7415-7419.
88. Smith GL, Mackett M, Moss B. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 1983;302:490-495.
89. Wiktor TJ, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA 1984;81:7194-7198.
90. Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985;227:433-435.
91. Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 1985;228:737-740.
92. Mackett M, Arrand JR. Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J 1985;4:3229-3234.
93. Perkus ME, et al. Live attenuated vaccinia and other poxviruses as delivery systems: public health issues. Ann N Y Acad Sci 1995;754:222-233.
94. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
95. Tartaglia J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
96. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors - NYVAC and ALVAC. Dev Biol Stand 1994;82:65-69.
97. Taylor J, et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992;187:321-328.
98. Taylor J, et al. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol 1991;65:4263-4274.
99. Gomez CE, Najera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008;8:97-120.
100. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel 2003;6:161-168.
101. Marthas ML, et al. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 2011;29:3124-3137.
102. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
103. Cleghorn F, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 2007;46:222-230.
104. Goepfert PA, et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005;192:1249-1259.
105. Goepfert PA, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011;203:610-619.
106. Thongcharoen P, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46:48-55.
107. Cebere I, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006;24:417-425.
108. Peters BS, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007;25:2120-2127.
109. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011;52:1-7.
110. Santra S, et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 2004;101:11088-11093.
111. + T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine 2011;29:5399-5406.
112. + T effector memory cells protect against liver-stage malaria. J Immunol 2011;187:1347-1357.
113. Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 1988;25:189-195.
114. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-620.
115. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
116. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-154.
117. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000;18:861-926.
118. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 2003;3:36-50.
119. Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006;124:767-782.
120. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-126.
121. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-347.
122. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
123. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005;23:787-819.
124. + T-cell immunity. J Interferon Cytokine Res 2010;30:205-218.
125. Sedger LM, et al. Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol 2006;80:9300-9309.
126. Sedy JR, Spear PG, Ware CF. Cross-regulation between herpesviruses and the TNF superfamily members. Nat Rev Immunol 2008;8:861-873.
127. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004;202:49-66.
128. Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002;196:829-839.
129. Glenney GW, Wiens GD. Early diversification of the TNF superfamily in teleosts: genomic characterization and expression analysis. J Immunol 2007;178:7955-7973.
130. Isaacs SN. A stimulating way to improve T cell responses to poxvirus-vectored vaccines. J Clin Invest 2011;121:19-21.
131. + T cells. J Virol 2004;78:3811-3816.
132. Hammarlund E, Lewis MW, Hanifin JM, Mori M, Koudelka CW, Slifka MK. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003;9:1131-1137.
133. Combadiere B, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004;199:1585-1593.
134. Hsieh SM, Pan SC, Chen SY, Huang PF, Chang SC. Age distribution for T cell reactivity to vaccinia virus in a healthy population. Clin Infect Dis 2004;38:86-89.
135. Kim SH, Oh MD. Persistence of cell-mediated immunity to vaccinia virus. J Infect Dis 2007;196:805-806.
136. + T cells. J Immunol 2008;181:7969-7976.
137. + T cells. J Immunol 2009;182:2909-2918.
138. + T cell-mediated resistance to an acute viral disease in a natural host. J Immunol 2006;177:8027-8036.
139. + T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells. Eur J Immunol 2007;37:716-728.
140. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-285.
141. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005;17:275-281.
142. Peperzak V, Xiao Y, Veraar EA, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010;120:168-178.
143. + T cells upon CD27 costimulation. J Immunol 2010;185:6670-6678.
144. + T cells. J Immunol 2008;180:2912-2921.
145. Pippig SD, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 1999;163:6520-6529.
146. Kopf M, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 1999;11:699-708.
147. Dawicki W, Bertram EM, Sharpe AH, Watts TH. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004;173:5944-5951.
148. + memory T cells and their capacity for secondary expansion. J Immunol 2005;175:1665-1676.
149. + T Cells: a CD4-dependent mechanism. J Immunol 2007;179:2195-2202.
150. + T cells for clonal expansion and memory formation. J Immunol 2006;177:1746-1754.
151. Ranasinghe C, et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006;24:5881-5895.
152. + T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol 2006;177:6336-6343.
153. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002;20:1862-1869.
154. + T cells in rhesus monkeys immunized with HIV vaccine. Cell Mol Immunol 2010;7:491-494.
155. Zielinski RJ, et al. Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys. Vaccine 2010;28:7081-7091.
156. Poon LL, et al. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 2009;182:3063-3071.
157. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 2003;100:3392-3397.
158. + T cell responses. Hum Gene Ther 2005;16:348-360.
159. Barr TA, Carlring J, Heath AW. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006;24:3399-3407.
160. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006;24:4975-4986.
161. + T-cell populations that protect against respiratory poxvirus infection. J Virol 2011;85:9051-9059.
162. + T cells in the lung airways retain the potential to mediate recall responses. J Immunol 2003;171:3338-3342.
163. Cerwenka A, Morgan TM, Harmsen AG, Dutton RW. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med 1999;189:423-434.
164. Du X, et al. The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination. J Gene Med 2007;9:136-146.
165. Xiao C, et al. Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants. Antiviral Res 2007;76:11-20.
166. + T-cell activation, protection from apoptosis, and enhanced cytokine production. Cell Immunol 2003;222:45-57.
167. Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009;27:5077-5084.
168. Weinberg AD, et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 2006;29:575-585.
169. + T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004;112:559-566.
170. Humphreys IR, et al. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 2003;170:6125-6132.
171. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-431.
172. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28:57-78.
173. Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg AD. OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. Eur J Immunol 2011;41:1024-1034.
174. + T cell survival. J Immunol 2008;180:2140-2148.
175. + memory T cell survival and significantly increases recall responses. Eur J Immunol 2007;37:157-166.
176. Williams CA, Murray SE, Weinberg AD, Parker DC. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol 2007;178:7694-7702.
177. + T cells that become IL-7 dependent. J Immunol 2007;179:2203-2214.
178. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005;105:2845-2851.
179. Stebbings R, Poole S, Thorpe R. Safety of biologics, lessons learnt from TGN1412. Curr Opin Biotechnol 2009;20:673-677.
180. Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human allograft injury. J Immunol 2005;175:4886-4896.
181. de Parseval A, Chatterji U, Morris G, Sun P, Olson AJ, Elder JH. Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus. Nat Struct Mol Biol 2005;12:60-66.
182. Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, Yamamoto N. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 2001;75:6748-6757.
183. Pankow R, et al. The HTLV-I tax protein transcriptionally modulates OX40 antigen expression. J Immunol 2000;165:263-270.
184. Imura A, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood 1997;89:2951-2958.
185. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 1989;8:4251-4258.
186. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol 1995;69:5391-5400.
187. DeLuca C, Petropoulos L, Zmeureanu D, Hiscott J. Nuclear IkappaBbeta maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells. J Biol Chem 1999;274:13010-13016.
188. Benedict CA, et al. Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol 2004;78:741-750.
189. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001;20(Suppl):S27-S31.